Fondaparinux sodium was initially approved by the United States Food and Drug Administration (FDA) for medical use on November 29, 2001.

Fondaparinux sodium is a medication with several important uses in preventing and treating blood clotting disorders. It is primarily employed to reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in situations where clot formation is more likely, such as after orthopedic surgeries like hip or knee replacements. It is also utilized to manage acute coronary syndromes (ACS). In addition to its role in preventing these serious conditions, it can be part of the treatment regimen for established cases of DVT and PE, helping to reduce the size of existing blood clots and prevent the formation of new ones.

Fondaparinux sodium is typically administered via subcutaneous injection. It is important to follow the dosing instructions as your healthcare provider recommends. 

Fondaparinux sodium can cause common side effects like bleeding at the injection site, nausea, fever, and liver function abnormalities. The primary concern is bleeding, which can range from mild to severe. Rarely, it may lead to thrombocytopenia, hypersensitivity reactions, or spinal/epidural hematomas, which can cause paralysis. 

Fondaparinux Sodium is an anticoagulant that increases the risk of bleeding. Serious and potentially life-threatening bleeding events can occur.  It can significantly increase the risk of developing spinal or epidural hematomas, especially in individuals undergoing spinal or epidural anesthesia or procedures. These hematomas can compress the spinal cord and lead to paralysis. It can cause a decrease in platelet counts (thrombocytopenia), which may increase the risk of bleeding. 

Caution should be exercised in patients with a higher risk of bleeding, such as those with bleeding disorders, recent surgeries, or conditions that may increase bleeding tendencies after taking Fondaparinux Sodium.  Extreme caution is needed when considering spinal or epidural procedures in patients receiving this medication. Platelet counts should be monitored regularly.

Caution is needed in cases of renal and hepatic impairment while taking Fondaparinux Sodium, and special attention should be given to patients undergoing spinal or epidural procedures due to the potential for hematoma. Monitoring of platelet counts, renal function, and coagulation parameters is essential. Hypersensitivity reactions, pediatric use, and the use during pregnancy or breastfeeding should be carefully considered. Elderly patients may require closer monitoring, and potential drug interactions and alcohol consumption should be discussed with a healthcare provider. Patients should exercise caution in activities that may lead to injury due to the increased risk of bleeding.

1. GlaxoSmithKline Pharmaceuticals Limited, US Food and Drug Administration, [Accessed on 27th Sept 2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021345s010lbl.pdf. 
2. Dr. Reddy’s Laboratories (UK) Ltd, Electronic Medicines Compendium (EMC), [Revised on 4th May 2022] [Accessed on 27th Sept 2023], https://www.medicines.org.uk/emc/files/pil.9756.pdf
3. James L. Zehnder, Drugs Used in Disorders of Coagulation, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 608-625.
4. Kumar et al., Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis, Journal of the American Heart Association, 2019, https://pdfs.semanticscholar.org/79e3/238225d5e7a5c08ea60f3c2d5aa5877bae0e.pdf?_ga=2.48382756.368595277.1626168591-44692483.16183266

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.